Date | Product | Disease | Phase | Company | Therapeutic area |
---|---|---|---|---|---|
2012-12-06 | reparixin | HER-2 negative metastatic breast cancer | 1b | Dompé (Italy) | Cancer - Oncology |
2012-12-06 | human fibrinogen concentrate | congenital fibrinogen deficiency | 1-2 | Biotest (Germany) | Blood diseases - Hematological diseases |
2012-12-05 | 4SC-205 | cancer | 1 | 4SC (Germany) | Cancer - Oncology |
2012-12-03 | GLPG0634 | rheumatoid arthritis |
1 | Galapagos (Belgium) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
2012-12-03 | CicloMulsion® (Cremophor®-free intravenous cyclosporine formulation) | 1 | NeuroVive Pharmaceutical (Sweden) | ||
2012-12-03 | Erwinaze® (asparaginase Erwinia chrysanthemi) | acute lymphoblastic leukemia with hypersensitivity to E. coli-derived asparaginase therapy. | Jazz Pharmaceuticals (Ireland) | Cancer - Oncology | |
2012-11-30 | talactoferrin alfa | severe sepsis non-small cell lung cancer (NSCLC) |
3 | Agennix (Germany) | Cancer - Oncology, Infectious diseases |
2012-11-29 | gevokizumab (XOMA 052/S 78989) | reduction of arterial wall inflammation in patients with marked atherosclerotic plaque inflammation |
Servier (France) Xoma (USA - CA) | Cardiovascular diseases | |
2012-11-29 | L19 antibody construct labeled with actinium 225 | glioblastoma multiforme |
preclinical | Actinium Pharmaceuticals (USA) Philogen (Italy) | Cancer - Oncology |
2012-11-29 | PRS-190 bispecific Anticalin program | Pieris (Germany) | |||
2012-11-26 | new undisclosed class of antibiotics | multiple drug-resistant (MDR) infections | Galapagos (Belgium) | Infectious diseases | |
2012-11-25 | mRNA vaccines | influenza A | preclinical data | CureVac (Germany) Friedrich-Loeffler-Institute (FLI - Germany) | Infectious diseases |
2012-11-22 | BAL30072 (sulfactam antibiotic) | multidrug-resistant Gram-negative infections |
1 | Basilea Pharmaceutica (Switzerland) | Infectious diseases |
2012-11-20 | AB103 | necrotizing soft tissue infections (NSTI) | 2a | Atox Bio (Israel) | Infectious diseases |
2012-11-20 | TNF-Kinoid® | Crohn’s disease | 2 | Neovacs (France) | Autoimmune diseases - Inflammatory diseases - Digestive diseases |
2012-11-19 | Varisolve® (now Varithena® - polidocanol endovenous microfoam (PEM) | treatment for patients with saphenofemoral junction incompetence and symptomatic and/or visible varicose veins | 3 | BTG International (UK) | Cardiovascular diseases |
2012-11-19 | MyeloXen™ | multiple sclerosis | 1-2a | Xenetic Biosciences (UK) | Autoimmune diseases - Neurodegenerative diseases |
2012-11-19 | stem cells | diabetes diabetic complications |
National University of Ireland (Ireland) - Orbsen Therapeutics (Ireland) | Metabolic diseases | |
2012-11-14 | Lemtrada® (alemtuzumab) | multiple sclerosis |
3 | Genzyme (USA - MA), a Sanofi company (France) | Autoimmune diseases - Neurodegenerative diseases |
2012-11-14 | Viaskin HDM | house dust mites allergy |
DBV Technologie (France) | Allergic diseases - Immune diseases |